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Abstract 
Background: Vertical transmission from mother to baby is an important route of  transmission for hepatitis B virus 
infection. Neonates who contract hepatitis B will have an almost 90 % risk of developing chronic HBsAg carriage and 
chronic liver disease. Neonatal immunization interrupts this vertical transmission. 
Objective: To determine the sero-prevalence of HBsAg among pregnant women and to identify potential risk factors 
associated with the infection. 
Methods: A cross-sectional study was conducted from October, 2002 to March, 2003 in a total of 493 pregnant 
women attending Mother and Child Health clinics of Jimma university specialized hospital and its Training Health 
Centers. Serum was collected from each woman and tested for the presence of HBsAg using Bioline Strip, which is a 
qualitative, solid phase two site sandwich immunoassay (Pacific Biotech, Thailand). A pre-structured questionnaire 
was used to collect socio-demographic data and to find out possible risk factors.  
Results: The overall prevalence of HBsAg was 3.7% ranging from 1.4% to 6.4%. It was highest in Jimma and lowest 
in Shebe town. The socio-demographic status of the study population shows that high proportion of HBsAg positivity 
was among the illiterate (61%), those whose income <500 Birr / month (88.9%) and among the Oromo ethnic 
subgroup (83%). Pregnant women who experience abortion had a higher prevalence of HBsAg (7.3%). The odds of 
having HBsAg was more than twice with those with history of abortion than with other risk factors. When pregnant 
women of Jimma town were separately analyzed, dental procedure, cesarean section and tattooing are associated with 
HBsAg positivity, unlike other towns. 
Conclusion: The prevalence of HBsAg carrier state in the study area was significant enough to start routine antenatal 
screening for HBsAg. Except for abortion, known risk factors included in the study were not associated with Hepatitis 
B virus infection. The main route of HBV transmission in Jimma and its neighboring towns could be either through 
sexual contact or from mother to child. Further studies are required to confirm these modes of transmission. 
[Ethiop.J.Health Dev. 2005;19(1):45-50] 
 
Introduction 
Hepatitis B virus (HBV) occurs worldwide and 
constitutes a serious public health problem. Globally, 
more than 2 billion people have been infected with HBV 
at some time in their lives. Of these, about 350 million 
people remain infected chronically and become carriers 
of the virus, and 1.5 million deaths occur from HBV 
related liver diseases, including end stage cirrhosis and 
hepatocellular carcinoma each year  (1- 3).  
 
Three major routes spread HBV: perinatal, horizontal, 
and sexual transmission (4). In developing countries, the 
main routes of transmission are: neonatal with HBV 
carrier mother infecting her infant usually during birth or 
soon after birth following close contact, transfer of HBV 
via cuts, sexual transmission, transfusion of infected 
blood or blood products, needle stick injury, 
contamination of eye, re-use of HBV contaminated 
needles, syringes, lancets and instruments including those 
used in tribal ceremonies, possibly blood sucking insects 
and bed bugs (2). 
 
Adults infected with HBV usually acquire acute hepatitis 
B and recover, but 5-10% develop the chronic carrier 
state.  Infected children rarely develop acute disease, but 
25 to 90% become chronic carriers (5). Neonates who 
contract hepatitis will have an almost 90% risk of 
developing chronic HBsAg carriage and chronic liver 
disease. Infants may also spread the disease to siblings 
and to a community (6). 
 
The global prevalence of chronic HBV infection varies 
widely, from high (>/=8%, e.g., Africa, Asia, and the 
western Pacific) to intermediate (2-7%) e.g. Southern and 
Eastern Europe) and low (<2%, e.g. Western Europe, 
North America and Australia (5). Most countries in 
Africa have high HBV endemicity, with the exceptions of 
Tunisia and Morocco, which have intermediate 
endemicity (7,8).   
 
In an earlier study done to define the mode of 
transmission of Hepatitis B infection in Ethiopia, 5% of 
pregnant women were reported to be positive for HBsAg 
(9). In another study done to determine the prevalence 
and significance of sexually transmitted diseases among 
Ethiopian women attending antenatal care (ANC) in 
Addis Ababa hospitals, the prevalence of HBsAg among   
pregnant women were similar (5%) to the above study      
(10). A survey of Ethiopian blood donors shows that 
occurrence of HBsAg was 8% (11). Similar study in 
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northwest Ethiopia reported that HBsAg was detected in 
14.4 % of blood donors (12). Moreover, a community-
based sero-epidemiological survey of Addis Ababa was 
conducted to inform on the transmission dynamics and 
control of HBV infection. HBsAg prevalence was 7%. 
Overall HBV seroprevalence (any marker), rose steadily 
with age to over 70% in 40-49 year olds, indicating 
significant childhood and adult transmission (13). 
 
Even though many studies on sero-epidemiology of HBV 
prevalence in Ethiopia have been previously done and 
indicated that hepatitis B is endemic in Ethiopia with 
regional variation (9-13), no data about the prevalence of 
hepatitis B among pregnant women are available in 
Jimma and its neighboring towns. The present study was 
conducted to determine the prevalence of HBsAg among 
pregnant women and to identify risk factors associated 
with hepatitis B infection in these areas.  
 
Methods 
Study design: A cross sectional study was conducted in 
Jimma University Specialized hospital and its four 
training health centers (i.e., Jimma, Asendabo, Agaro and 
Shebe health centers) among pregnant women attending 
Mother and Child Health (MCH) department from Oct. 
2002 to Mar. 2003.  
 
Study population: - A total of 493 pregnant mothers who 
were attending MCH clinics in the above mentioned 
health institutions were included in this study.  Informed 
consent was obtained before data collection. 
 
Steps of data collection- 
I. Socio-demographic characteristics and exposure to 
risk factors 
An MCH nurse was identified in each health institution 
to interview the subjects and enter the data according to 
the pre-structured questionnaire. The questionnaire 
included level of education, occupation, income, 
ethnicity, and history of dental and surgical procedure, 
tattooing, exposures to unsafe injection, history of 
caesarian section, abortion, liver disease, blood 
transfusion and ear piercing in jewelers shop. 
 
II. Serological detection of Hepatitis B surface antigen 
Sample: - Fresh serum was obtained by centrifuging 
naturally clotted blood. The serum sample was kept in 
the refrigerator at 4°C and transported to Jimma 
University Medical Laboratory School. 
 
Bioline HBsAg One Test: -The Bioline HBsAg One 
Test is a qualitative, solid phase, two-site sandwich 
immunoassay for the detection of HBsAg in serum or 
plasma. The membrane is pre-coated with anti-HBsAg 
antibodies on the test band region and anti-mouse 
antibodies on the control band region. During testing, the 
serum sample reacts with the dye conjugate (mouse anti-
HBsAg antibody colloidal gold conjugate) that has been 
coated in the test strip. The mixture then by capillary 
action, reacts with anti-HBsAg antibodies on the 
membrane and generates a red band. Presence of this red 
band indicates a positive result while its absence 
indicates a negative result. Regardless of the presence of 
HBsAg, as the mixture continues to migrate across the 
membrane to the immobilized   goat anti-mouse region a 
red band at the control band region will always appear. 
The presence of this red band serves as verification for 
sufficient sample volume and proper flow and as a 
control for the reagents. 
 
Briefly, the procedure is as follows: 
1) The Bioline HBsAg test strip was removed from foil 
pouch. 
2) The test strip in the serum samples was immersed with 
printed sample pointing toward the serum or plasma.  
3) Then waited for the red bands to appear. The test was 
read after approximately 5 minutes. Results after 30 
minutes were not interpreted.  
 
Interpretation of the test: 
Positive - Two distinct red bands appear, one in test 
region and another in the control region.  
Negative - A single red band appears in the control 
region. No apparent red or pink band appears in the test 
region. 
Invalid - Control band fails to appear which means 
improper testing procedure or deterioration of   reagents 
probably. 
 
Accuracy of the Bioline HBsAg strip 
Bioline HBsAg was compared with a leading commercial 
Radio immunoassay (RIA) and an Enzyme immunoassay 
(EIA) test for Hepatitis B. There was 98% overall 
agreement between RIA and Bioline HBsAg and 97% 
between EIA and Bioline HBsAg. Bioline HBsAg will 
detect any level of HBsAg in serum higher than 5ng /ml 
within 10 min. However, to detect concentrations below 
5ng/ml and to confirm negative results, the test should be 
read at the end of 15 to 20 min. All ten HBsAg subtypes 
(ayw1, ayw2, ayw3, ayw4, aayr, adw2, adw4, adrg +adr 
and adr) produce a positive result in HBsAg assay (14). 
 
Statistical analysis: -Descriptive statistics, and Chi-
square test with Yate’s correction is used to determine for 
any association between socio-demographic 
characteristics, exposure to risk factors. P< 0.05 is 
considered as having significant association. Odds ratio 
was used to compare seropositivity of HBsAg with 
history exposure to risk factors. 
 
Results 
Out of 493 sera from pregnant women tested for HBsAg, 
18 (3.7%) were positive, ranging from 1.4 % to 6.4% for 
each training health center and Jimma University’s 
specialized hospital. It was highest in Jimma and lowest 
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in Shebe town. Results of area-specific serological test 
are shown in Table 1.  
 
Table 1:  Prevalence of HBsAg of pregnant women 
attending Jimma University Hospital and its training 
health centers in 2002/03 
Site No. tested (%) HBsAg Positive (%) 







Agaro H.C 100 (20.3) 3 (3.0) 
Asendabo H.C 96 (19.5) 2 (2.1) 
Shebe H.C 86 (17.4) 1 (1.4) 
Total 493 (100) 18 (3.7) 
 
At least one seropositive case for HBsAg was found in 
all age groups except in the age range of 35 to 39. The 
highest age-specific prevalence was in the age group of 
>40; however, the total number of pregnant women 
tested was only four.  There was no linear relationship 
between prevalence of HBsAg and age in all the study 
sites. The seroprevalence of HBsAg in relation to age is 
shown in Table 2. 
 
The sociodemographic status of the study population 
shows that a high proportion of HBsAg positivity was 
among the illiterate 11/18(61%), those whose income 
was <500 Birr / month 16/18(88.9%) and among the 
Oromo ethnic subgroup 15/18(83%).  However, the 
overall prevalence of HBsAg   among the illiterate 
(3.5%) and Oromo ethnic group (4.1%) have no 
significant difference (p> 0.05) when compared with 
other educational status and ethnic groups, respectively. 
The prevalence among Dawro was two fold higher than 
among the Oromo and Keffa, and also five fold higher 
than among the Amhara pregnant women. HBV infection 
was not detected in both Gurage and Tigrean pregnant 
women. As far as monthly income was concerned the 
prevalence of HBsAg decreases as the income increases 
(p<0.05) (Table 3). 
 
Table 2:  Prevalence of HBsAg in relation with age of pregnant women attending Jimma University hospital and its 
training health centers in 2001/03 
Age Jimma hospital Jimma* 
No. tested (%) 
Agaro* 
No. tested (%) 
Asendabo* Shebe* Total 
15-9 28 (10.7) 24 (8.3) 25 (0.0) 26 (3.8) 28 (0.0) 131 (4.6) 
20-24 51 (0.0) 22 (4.5) 41 (2.4) 34 (0.0) 29 (0.0) 177 (1.1) 
25-29 41 (7.3) 14 (0.0) 18 (5.6) 25 (4.0) 12 (18.3) 110 (5.5) 
30-34 12 (16.7) 9 (0.0) 11 (9.1) 6 (0.0) 8 (0.0) 45 (6.7) 
35-39 7 (0.0) 2 (0.0) 4 (0.0) 5 (0.0) 7 (0.0) 25 (0.0) 
>40 1 (100) 0 (0.0) 1 (0.0) 0 (0.0) 2 (0.0) 4 (25) 
Total 140  71  100  96  86 493 (3.7) 
* Health Center 
 
Table 3:  Prevalence of HBs Ag in relation to socio demographic characteristics of pregnant women attending Jimma 
University hospital and its training health centers in 2002/03 











#     (%) 
Education       
Illiterate 32 58 72 86 68 316 (3.5) 
<6 30 2 3 15 15 52 (7.7) 
7-8 19 5 12 3 3 44 (0.0) 
9-12 44 5 13 3 0 65 (4.6) 
12+ 15 1 0 0 0 15 (0.0) 
Occupation       
Government employee 27 3 4 1 4 39 (0.0) 
House wife 96 64 89 94 78 418 (3.8) 
Student 9 1 0 1 0 11 (18.2) 
Merchant 4 0 3 0 0 7 (0.0) 
House maid 1 0 0 0 2 3 (0.0) 
No work 3 3 4 0 2 12 (0.0) 
Income (in Birr)       
<500 81 62 90 86 64 383 (3.9) 
500-1000 52 9 9 6 16 92 (3.3) 
>1000 7 0 1 4 6 18 (0.0) 
Ethnicity       
Oromo 82 60 73 87 62 364 (4.1) 
Amhara 18 3 14 1 12 48 (2.1) 
Keffa 13 0 0 0 8 21 (4.8) 
Gurage 6 0 8 5 0 19 (0.0) 














 24 (4.2)         
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Pregnant women who experienced abortion had higher 
prevalence of HBsAg (7.3%) and the odds of having 
HBsAg was more than twice with those pregnant women 
that had history of abortion than with other risk factors 
(p<0.05).  Other risk factors included in the study had not 
statistically significant association (p>0.05) with the 
HBsAg positivity (Table 4). 
 
Table 4:  Potential risk factors and prevalence of HBsAg in Jimma University's hospital and its training health 
centers in 2002/03 
Risk factors No. (%) No. HBsAg positive (%) Odds ratio (95% CI) 
Dental procedure 33 (6.7) 1 (5.6) 0.8 (0.70-0.91) 
Surgical procedure 20 (4.1) 0 (0.0) 0.0 
Tattooing 84 (17.0) 2 (11.2) 0.6 (0.40-0.83) 
Unsafe injection 20 (4.1) 1 (5.6) 0.7 (0.65-0.75) 
Caesarian section 14 (2.8) 1 (5.6) 0.5 (0.39-0.63) 
Abortion 41 (8.3) 3 (16.8) 2.3 (1.0105.30) 
Liver disease 6 (1.2) 0 (0.0) 0.0 
Blood transfusion 5 (1.0) 0 (0.0) 0.0 
Ear piercing 







No risk factors 335 (67.9) 10 (55.6) 0.6 (0.33-0.93) 
Total 493 (100) 18 (100)  
 
Discussion 
The overall prevalence of HBsAg in pregnant women 
from Jimma and its neighboring towns was 3.7%.  This 
places Ethiopia, specifically the Oromia region, as a 
medium endemic area (2-7 % of HBsAg positive) for 
HBV infection according to WHO criteria (8). But the 
prevalence of each town differs widely.  It was highest in 
the relatively densely populated towns of Jimma (Jimma 
Hospital, 6.4% and Jimma Health Center, 4.6%) and 
Agaro (Agaro Health Center, 3%). 
 
The results from this study are in agreement with the 
investigation done among pregnant women in Lebanon 
2.9% (15), Turkey 4.3% (16) and India 4.6% (5). Lower 
and higher prevalence rates were also detected in similar 
study populations in different parts of the world. 
Countries with lower prevalence include United States 
with 0.14% – 0.97% in different races, except among 
Asian American where prevalence was 5.6%, (17), Brazil 
1.05% (18) and Mexico 1.65% (19). 
 
Higher prevalence of 6.5% each was reported among a 
similar study population in Congo and Zambia (20, 21), 
Hong Kong 10% (21), Papua New Guinea 11% (22), 
Nigeria 11.6% (23) and Taiwan 12% (24). Extremely 
high prevalence (25.3%) was also reported in Cameroon 
(25). 
 
Since there are no previous data from our study area we 
are unable to compare for trend. However, there were 
two earlier studies conducted among pregnant women in 
Addis Ababa hospitals that reported 5% in both studies 
(9, 11), which was a little higher than our result. 
 
The prevalence of HBsAg positivity in this study was not 
limited to any particular age group and was almost 
equally distributed among all the age subgroups of 
pregnant women, even though no HBsAg positive 
pregnant woman was detected among the age group 
between 35-39. Since only 7 pregnant women were in 
this age group, it is not representative to generalize for 
the status of the whole subgroup. 
 
When age specific prevalence is considered, age group 
>40 years and between 30-34 years of age have a higher 
prevalence of 25% and 6.7% respectively. The 
prevalence of the latter age group agrees with a similar 
study done in Central America (26). Whereas in the 
former subgroup only 4 pregnant women participated in 
the study and one was positive for HBsAg as a result the 
prevalence may be inflated unless confirmed by another 
study involving a larger sample size. 
 
The HBsAg positivity rate among those tested varies 
widely by ethnicity with highest in Dawro (11.1%) 
followed by Keffa  (4.8%) Oromo (4.1%) and Amhara 
2.1%.  No HBsAg was detected in the Tigrean and 
Gurage ethnic groups. A remarkable geographical and 
ethnic variability of marker prevalence was shown in a 
previous nation wide study (9).  However, our study 
shows only small difference and this may be due to the 
fact that the sample size of ours is about 1/10th of this 
earlier study. 
 
Risk factors, including blood transfusion, surgery, liver 
disease, dental and surgical procedures, and tattooing 
were not associated with HBV infection in this study as a 
whole. But when pregnant women of Jimma town were 
separately analyzed, those who history of caesarian 
section, dental procedure and tattooing had association 
which HBV infection. The odds of having HBsAg with 
caesarian section and dental procedure was twice and 
with tattooing was thrice, as compared with those who 
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did not experience these risk factors.  These differences 
should be confirmed in further studies.  
This study revealed an association between HBsAg 
positivity and history of abortion. Having history of 
abortion increased the risk of having HBV infection more 
than twice as compared with those who had not suffered 
such experience. As it is known, abortion is directly 
related to sexually active women, and one most important 
mode of transmission for HBV is exposure to a 
heterosexual partner (10). Therefore, other reasons such 
as instrumentation during abortion and related activities 
may serve as source of exposure.  
 
A previous study identified that there was a significant 
association between HBsAg positivity and exposure to 
heterosexual partner. Because of the issue of 
confidentiality, information about sexual practices was 
not included in this study. In addition, past history of 
sexually transmitted diseases is significantly associated 
with HBsAg positivity when compared with the normal 
pregnant women. In general, women of child bearing age 
who are living in more urbanized areas may have more 
HBV exposure than those in the rural population, as a 
result of risky life style practices (26). 
 
Previous report shows that universal prenatal screening 
for HBsAg is cost effective if the   HBsAg carrier rate is 
greater than 0.06% (16). Thus, our findings affirmed the 
need for routine HBsAg screening among pregnant 
women in developing countries like Ethiopia.  
 
Although WHO recommended that hepatitis B vaccine be 
incorporated into routine infant and childhood 
immunization program for all countries by 1997, only 
130 of 216 countries introduced hepatitis B immunization 
into their national infant and childhood immunization 
programme by the beginning of 2001. The major hurdle 
to universal hepatitis B immunization is the cost of 
hepatitis B vaccine, especially for developing countries. 
Even though the price of hepatitis B vaccine for 
developing countries has dropped from about $3.00 per 
dose in 1990 to as low as $ 0.30 per dose in 2001, the 
cost of three doses of hepatitis B vaccine remains higher 
than the cost of other vaccines included in routine infant 
immunization programmes (27). 
 
In conclusion, except abortion, known risk factors 
included in the study were not associated with Hepatitis 
B virus infection. The main route of HBV transmission in 
Jimma and its neighboring towns could be either through 
sexual contact or from mother to child. In order to 
determine the extent of perinatal transmission of HBV, 
the prevalence of HBeAg among the HBsAg carrier 
mothers should be determined in a further study. Due to 
the small sample size, although most point estimates 
were comparable to other published data, it was difficult 
to conclude the age specific prevalence, and the role of 
ethnic sub-groups and risk factors associated with HBV 
infection in this study. Hence, a further study is required. 
Preferably, to have a good contrast, both pregnant and 
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